Inhibikase Therapeutics, Inc. Common Stock (IKT) Stock Price

IKTStock

$2.50+32.28%52W

Market Cap$348.84M

P/E—

PEG Ratio—

Div yield—

Beta0.91

IKT Share Price Chart

Favorite Metrics

Price vs S&P 500 (26W)27.64%

Price vs S&P 500 (4W)5.17%

VGM Score47.34

Book Value / Share (Quarterly)$1.27

P/TBV (Annual)0.26x

Indicated Dividend (Annual)$0.00

Cash Flow / Share (Quarterly)$-0.27

Price vs S&P 500 (YTD)9.99%

Net Profit Margin (TTM)-5981.25%

EPS (TTM)$-1.15

10-Day Avg Trading Volume0.45M

EPS Excl Extra (TTM)$-1.15

EPS (Annual)$-1.16

ROI (Annual)-29.01%

Net Profit Margin (5Y Avg)-4748.27%

Cash / Share (Quarterly)$1.29

ROA (Last FY)-27.91%

EBITD / Share (TTM)$-0.71

ROE (5Y Avg)-71.16%

Operating Margin (TTM)-6253.12%

Cash Flow / Share (Annual)$-0.21

P/B Ratio2.01x

P/B Ratio (Quarterly)1.32x

Net Income / Employee (Annual)$-786,300

EV / Revenue (TTM)895.96x

Net Interest Coverage (TTM)-738.50x

ROA (TTM)-52.76%

EPS Incl Extra (Annual)$-1.16

Current Ratio (Annual)21.70x

Quick Ratio (Quarterly)29.83x

3-Month Avg Trading Volume0.82M

52-Week Price Return32.28%

Revenue / Employee (TTM)$0

Tangible BV / Share (Quarterly)$2.80

P/S Ratio (Annual)1290.91x

Asset Turnover (Annual)0.02x

52-Week High$2.54

Operating Margin (5Y Avg)-4841.72%

EPS Excl Extra (Annual)$-1.16

26-Week Price Return38.89%

Quick Ratio (Annual)21.54x

13-Week Price Return43.68%

Total Debt / Equity (Annual)0.00x

Current Ratio (Quarterly)30.14x

Enterprise Value$286.71M

Asset Turnover (TTM)0.01x

Book Value / Share Growth (5Y)-25.76%

Revenue / Employee (Annual)$0

Pretax Margin (Annual)-7304.75%

Cash / Share (Annual)$1.36

3-Month Return Std Dev47.77%

Net Income / Employee (TTM)$-1,361,600

ROE (Last FY)-29.01%

Net Interest Coverage (Annual)-178.00x

EPS Basic Excl Extra (Annual)$-1.16

P/FCF (TTM)4203.52x

Receivables Turnover (TTM)6.67x

Total Debt / Equity (Quarterly)0.00x

EPS Incl Extra (TTM)$-1.15

Receivables Turnover (Annual)13.03x

ROI (TTM)-57.15%

P/S Ratio (TTM)1050.88x

Pretax Margin (5Y Avg)-4748.27%

Revenue / Share (Annual)$0.00

Tangible BV / Share (Annual)$5.00

Price vs S&P 500 (52W)13.96%

Year-to-Date Return21.95%

5-Day Price Return4.17%

EPS Normalized (Annual)$-1.16

ROA (5Y Avg)-57.11%

Net Profit Margin (Annual)-7304.75%

Month-to-Date Return14.68%

Cash Flow / Share (TTM)$-3.92

EBITD / Share (Annual)$-1.20

Operating Margin (Annual)-7712.01%

LT Debt / Equity (Annual)0.00x

ROI (5Y Avg)-70.92%

LT Debt / Equity (Quarterly)0.00x

EPS Basic Excl Extra (TTM)$-1.15

P/TBV (Quarterly)0.36x

P/B Ratio (Annual)1.44x

Pretax Margin (TTM)-5981.25%

Book Value / Share (Annual)$1.31

Price vs S&P 500 (13W)40.88%

Beta0.91x

P/FCF (Annual)473.64x

Revenue / Share (TTM)$0.00

ROE (TTM)-57.15%

52-Week Low$1.33

vGradeF

mGradeB

vgmGradeC

IKT Earnings Surprise History

Q2 25-0.11est. -0.08

Q3 25-0.13est. -0.13

Q4 25-0.09est. -0.12

Q2 26-0.11est. -0.09

IKT Analyst Recommendations

May 2026

Jun 2026

Jul 2026

Aug 2026

4.18

4.25

4.31

Industry Peers — Biological Products(183)

Symbol	Value Score	Growth Score	Momentum Score	Price
IKTInhibikase Therapeutics, Inc. Common Stock	F	—	B	$2.50
AMGNAmgen Inc	C	C	B	$442.24
GILDGilead Sciences Inc	C	B	B	$148.77
MRNAModerna, Inc. Common Stock	D	C	A	$158.83
ARGXargenx SE American Depositary Shares	D	A	B	$1019.49
RVMDRevolution Medicines, Inc. Common Stock	F	—	A	$211.38
BIIBBiogen Inc. Common Stock	C	D	B	$220.77
BNTXBioNTech SE American Depositary Share	C	C	B	$114.05
NBIXNeurocrine Biosciences Inc	C	B	C	$153.37
EXELExelixis Inc	C	B	B	$56.72
HALOHalozyme Therapeutics, Inc.	C	B	A	$109.32
TECHBio-Techne Corp.	D	C	B	$72.33
KRYSKrystal Biotech, Inc. Common Stock	D	B	B	$356.19
KYMRKymera Therapeutics, Inc. Common Stock	D	B	B	$126.64
RGENRepligen Corp	D	C	A	$181.69
APGEApogee Therapeutics, Inc. Common Stock	—	—	A	$134.85
TWSTTwist Bioscience Corporation Common Stock	D	B	A	$151.42
PCVXVaxcyte, Inc. Common Stock	—	—	B	$61.09
QGENQIAGEN N.V.	C	C	C	$43.65
IMVTImmunovant, Inc. Common Stock	—	—	B	$43.50
IBRXImmunityBio, Inc. Common Stock	F	A	C	$8.19
SRRKScholar Rock Holding Corporation Common Stock	F	—	B	$58.25
CGONCG Oncology, Inc. Common stock	F	A	A	$78.95
CRSPCRISPR Therapeutics AG	D	B	B	$60.90
RLAYRelay Therapeutics, Inc. Common Stock	F	D	A	$20.57
ADPTAdaptive Biotechnologies Corporation Common Stock	D	B	A	$26.25
DNLIDenali Therapeutics Inc. Common Stock	F	—	B	$24.93
IOVAIovance Biotherapeutics, Inc. Common Stock	C	B	A	$8.44
BEAMBeam Therapeutics Inc. Common Stock	C	B	B	$31.03
TARSTarsus Pharmaceuticals, Inc. Common Stock	D	A	B	$71.45
BCRXBioCryst Pharmaceuticals Inc	B	A	B	$9.83
KODKodiak Sciences Inc Common Stock	—	—	B	$39.46
COAGHemab Therapeutics Holdings, Inc. Common Stock	—	—	B	$49.65
MESOMesoblast Limited American Depositary Shares	D	B	C	$17.19
VCELVericel Corporation	D	B	C	$43.22
ADMAADMA Biologics, Inc.	C	C	C	$9.72
TSHATaysha Gene Therapies, Inc. Common Stock	F	B	B	$6.20
IMCRImmunocore Holdings plc American Depositary Shares	D	B	B	$37.40
RXRXRecursion Pharmaceuticals, Inc. Class A Common Stock	D	C	C	$3.56
VIRVir Biotechnology, Inc. Common Stock	B	B	B	$10.71
INBXInhibrx Biosciences, Inc. Common Stock	D	C	B	$122.72
ALVOAlvotech Ordinary Shares	C	D	B	$5.05
MAZEMaze Therapeutics, Inc. Common Stock	—	—	B	$30.42
NVAXNovavax Inc	B	D	C	$9.44
REPLReplimune Group, Inc.	—	—	A	$15.80
SLBTSL Science Holding Limited Ordinary Shares	—	—	F	$2.64
MGTXMeiraGTx Holdings plc Ordinary Shares	D	C	A	$14.92
VORVor Biopharma Inc. Common Stock	—	—	B	$24.01
CGEMCullinan Therapeutics, Inc. Common Stock	—	—	A	$22.95
IMTXImmatics N.V. Ordinary Shares	C	D	C	$9.24
ODTXOdyssey Therapeutics, Inc. Common Stock	—	C	A	$26.23

About Inhibikase Therapeutics, Inc. Common Stock

Inhibikase Therapeutics is a clinical-stage biopharmaceutical company developing selective protein kinase inhibitors for neurological disorders. Its lead program, Risvodetinib (IkT-148009), targets Parkinson's disease and related conditions driven by Abelson Tyrosine Kinase dysfunction. The company focuses on disease-modifying therapies for Parkinson's and other neurodegenerative conditions.